Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of monoclonal antibody against B cell maturation antigen and its application

A monoclonal antibody, B cell technology, applied in the field of biomedicine, can solve the problems of obvious side effects and insufficient clinical data, and achieve the effect of improving the killing ability

Active Publication Date: 2022-01-18
HUADAO SHANGHAI BIOPHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Allogeneic hematopoietic stem cell transplantation can eliminate myeloma cells, but this therapy has significant side effects and only a small number of people benefit
In addition, monoclonal antibodies also show some potential in the treatment of myeloma, but there is not enough clinical data to confirm

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of monoclonal antibody against B cell maturation antigen and its application
  • A kind of monoclonal antibody against B cell maturation antigen and its application
  • A kind of monoclonal antibody against B cell maturation antigen and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] This example is used for the construction and panning of phage monoclonal antibody library, and ELISA is used for preliminary screening. Specific steps are as follows:

[0061] (1) Construction of phage monoclonal antibody library

[0062] Bactrian camels were immunized with BCMA-Fc expressing the extracellular region, and after the titer was verified by ELISA, 200 mL of peripheral blood was drawn; lymphocytes were sorted, and peripheral blood mononuclear lymphocyte precipitates were obtained, and RNA was extracted; III reverse transcriptase uses RNA as a template to synthesize the first-strand cDNA, and then uses nested PCR to amplify the VHH gene; inserts the VHH gene into the pMECS phage display vector, and after electrotransforming TG1 competent cells, take an appropriate amount of bacterial liquid for library identification , all the remaining cultures were evenly spread on LB / AMPGLU plates, and the lawn was collected after the bacteria grew out, and 1 / 3 of the v...

Embodiment 2

[0076] In this example, the candidate clones were screened using the flow cytometry fluorescence sorting technique (Fluorescence activated Cell Sorting, FACS).

[0077] Carry out cell culture according to the standard cell culture protocol, use trypsin to digest cells to prepare BCMA-positive and negative cell suspensions; 6 cell / mL; Add 2×10 to each well in a V-bottom 96-well plate 5 After centrifuging at 300g for 5min, remove the supernatant, add the crude extract of VHH antibody to resuspend the cells, and incubate at 4°C for 1h;

[0078] After centrifuging at 300g for 5 minutes, remove the supernatant, resuspend the cells in Flow Buffer, dilute the APCanti-his antibody to 2 μg / mL with Flow Buffer, resuspend the cells in 100 μL per well, and incubate at 4 °C for 1 hour; wash the cells with Flow Buffer 3 times, then use 200 μL Flow Buffer Cells were resuspended and analyzed by flow cytometry.

Embodiment 3

[0080]In this example, the VHH-mIgG2a Fc monoclonal antibody was expressed and purified, and the antibody affinity was measured. In order to further identify the screened antibodies, the antibodies need to be expressed by mammalian cells. Therefore, a plasmid vector expressing VHH with a mouse Fc tag was firstly constructed, which was denoted as C-4pCP.Stuffer-mCg2a-FC, and the specific steps were as follows:

[0081] 1. Use PCR to amplify BCMA VHH B46, and its primers are:

[0082] HD-F (SEQ ID NO. 10):

[0083] CGCGATTCTTAAGGGTGTCCAGTGCGAGGTGCAGCTGGTGGA;

[0084] HD-B46-R (SEQ ID NO. 11):

[0085] GCATGGAGGACAGGGCTTGATTGTGGGAGAGCTCACTGTCACCTG

[0086] The reaction system is shown in Table 2, and the amplification program is shown in Table 3 below:

[0087] Table 2

[0088]

[0089] table 3

[0090]

[0091] 2. The enzyme digestion system is shown in Table 4. The enzyme digestion temperature is 37°C and the time is 6 hours. The PCR purification kit was used for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a monoclonal antibody against B cell maturation antigen and application thereof. The heavy chain variable region of the anti-B cell maturation antigen monoclonal antibody includes: complementarity determining region 1 shown in SEQ ID NO.1, complementarity determining region 2 shown in SEQ ID NO.2 and SEQ ID NO.3 Complementarity-determining region 3 is shown. In the present invention, the antibody obtained by screening the phage display nanobody library has a specific CDR region, and the obtained antibody can specifically bind to the BCMA antigen with good affinity, and its K a (1 / Ms) is 3.03E+06, K d (1 / s) is 2.14E‑04, K D (M) is 7.09E‑11. Therefore, the monoclonal antibody has broad application prospects in the immunotherapy of multiple myeloma.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a monoclonal antibody against B cell mature antigen and application thereof. Background technique [0002] Multiple myeloma (multiple myeloma, MM) is a tumor caused by the malignant proliferation of plasma cells. It is the second most common hematological malignancy. of a disease. Multiple myeloma is typically characterized by a large number of abnormally proliferating plasma cells in the bone marrow that secrete an abnormal immunoglobulin or immunoglobulin fragment, the M protein. [0003] Survival in multiple myeloma has improved markedly with the use of proteasome inhibitors such as bortezomib and immunomodulatory drugs such as lenalidomide. However, multiple myeloma still cannot be completely cured. Multiple myeloma is highly heterogeneous biologically and clinically, therefore, its response to multi-drug combination therapy and survival after treatment hav...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C12N15/13C07K19/00C12N15/867C12N5/10A61K39/00A61P35/00
CPCC07K16/2878C07K14/7051C07K14/70517C07K14/70578C12N5/0636C12N15/86A61K39/001117A61P35/00C07K2317/565C07K2317/56C07K2317/567C07K2319/02C07K2319/03C07K2319/33C07K2319/74C12N2740/15043C12N2800/107C12N2510/00A61K2039/5156A61K2039/804
Inventor 石磊狄升蒙童东阳龚鹏飞马祖良
Owner HUADAO SHANGHAI BIOPHARMA CO LTD